Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regenxbio Inc (RGNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
REGENXBIO Joins the Mucopolysaccharidosis Community to Advance Research and Innovation

ROCKVILLE, Md. , May 15, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy...

RGNX : 47.20 (+0.96%)
REGENXBIO Joins the Mucopolysaccharidosis Community to Advance Research and Innovation

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform,...

RGNX : 47.20 (+0.96%)
REGENXBIO to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform,...

RGNX : 47.20 (+0.96%)
REGENXBIO Reports First Quarter 2018 Financial Results and Recent Operational Highlights

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform,...

RGNX : 47.20 (+0.96%)
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2018 Financial Results and Recent Operational Highlights

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform,...

RGNX : 47.20 (+0.96%)
Consolidated Research: 2018 Summary Expectations for REGENXBIO, WD-40, Chesapeake Utilities, Astronics, Park-Ohio, and Cass Information -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of REGENXBIO Inc. (NASDAQ:RGNX),...

PKOH : 41.25 (-1.79%)
CASS : 62.99 (+0.53%)
WDFC : 139.25 (+0.76%)
RGNX : 47.20 (+0.96%)
ATRO : 35.53 (+0.28%)
CPK : 76.35 (-0.52%)
REGENXBIO Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights

-- Completed dosing of third cohort in RGX-314 Phase I clinical trial for wet AMD

RGNX : 47.20 (+0.96%)
REGENXBIO, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 6, 2018 / REGENXBIO, Inc. (NASDAQ: RGNX) will be discussing their earnings results in their Q4 Earnings Call to be held on March 6, 2018, at 4:30 PM Eastern Time.

RGNX : 47.20 (+0.96%)
REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD

-- Clinical trial evaluates one-time treatment for wet AMD using NAVAAV8 gene therapy

RGNX : 47.20 (+0.96%)
REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today...

RGNX : 47.20 (+0.96%)
REGENXBIO Enhances Gene Therapy Manufacturing Capabilities by Entering into Strategic Partnership with FUJIFILM Diosynth Biotechnologies

- REGENXBIO has established internal capability to produce NAV AAV across multiple platforms and at scale of up to 200L

RGNX : 47.20 (+0.96%)
Consolidated Research: 2018 Summary Expectations for REGENXBIO, Rexahn Pharmaceuticals, QuinStreet, NewMarket, Stock Yards, and United States Lime & Minerals -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of REGENXBIO Inc. (NASDAQ:RGNX),...

RNN : 2.16 (-0.92%)
QNST : 12.84 (-1.00%)
USLM : 78.45 (-1.16%)
RGNX : 47.20 (+0.96%)
NEU : 377.59 (-0.19%)
SYBT : 39.50 (-0.50%)
REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy

-- AveXis acquires exclusive rights to entire NAV Technology Platform for the development of treatments for SMA

RGNX : 47.20 (+0.96%)
AVXS : 217.94 (+0.05%)
REGENXBIO Provides Year-End 2017 Corporate Update

- Initiated third cohort dosing of RGX-314 Phase I clinical trial for wet AMD -

RGNX : 47.20 (+0.96%)
REGENXBIO Announces IND Active for Phase I/II Trial of RGX-121 to Treat Mucopolysaccharidosis Type II

-- Novel, one-time, direct-to-CNS treatment for MPS II focused toward potentially preventing the progression of cognitive deficits

RGNX : 47.20 (+0.96%)
REGENXBIO to Present at Upcoming Investor Conferences

REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today...

RGNX : 47.20 (+0.96%)
REGENXBIO Reports Third Quarter 2017 Financial Results and Recent Operational Highlights

-- Completed second cohort dosing in RGX-314 Phase I clinical trial for wet AMD

RGNX : 47.20 (+0.96%)
Puma (PBYI) Q3 Earnings: Will it Surpass Estimates Again?

Puma Biotechnology's (PBYI) only marketed product, Nerlynx (neratinib), for advanced breast cancer was launched in August. So Q3 is the first quarter in which Puma will record sales for Nerlynx.

PBYI : 51.60 (+1.28%)
RGNX : 47.20 (+0.96%)
INO : 4.84 (-0.41%)
PIRS : 6.11 (+1.16%)
BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?

BioDelivery Sciences (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact third-quarter results remains to be seen.

BDSI : 2.50 (+9.89%)
RGNX : 47.20 (+0.96%)
INO : 4.84 (-0.41%)
PIRS : 6.11 (+1.16%)
What's in the Cards for Merrimack (MACK) in Q3 Earnings?

Merrimack Pharmaceuticals (MACK) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

AGEN : 3.47 (-0.29%)
RGNX : 47.20 (+0.96%)
CDTX : 5.43 (+4.42%)
MACK : 8.49 (-1.62%)

Van Meerten Stock Picks

5 Great Growth Stocks
This morning I wanted to find 5 stocks that were predicted to have double digit growth in both Revenue and Earnings over the next 5 years that were also having great current performance.
LULU +1.14 , ABMD -1.06 , AAXN +2.28 , NSP +0.90 , ERI +1.00
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures were weak into the close on Thursday, down 3 to 4 1/4 cents lower in the front months. Traders were taking money off the table ahead of the extended weekend. The USDA reported a private cancelation of 132,000 of grain sorghum to unknown ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar